Randomized Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2017
At a glance
- Drugs ARI 3037MO (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms REASCEND
- Sponsors Arisaph Pharmaceuticals
- 05 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
- 05 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 27 Aug 2015 New trial record